NO329693B1 - Kimaerisk virus samt anvendelse derav, nukleinsyremolekyl og vaksinesammmensetning. - Google Patents

Kimaerisk virus samt anvendelse derav, nukleinsyremolekyl og vaksinesammmensetning. Download PDF

Info

Publication number: NO329693B1
Authority: NO; Norway
Prior art keywords: virus; flavivirus; prm; protein; chimeric
Prior art date: 1997-02-28

Application number

NO19994185A

Other languages

English (en)

Norwegian (no)

Other versions

NO994185D0 (no

NO994185L (no

Inventor

Thomas J Chambers

Thomas P Monath

Farshad Guirakhoo

Original Assignee

Univ St Louis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-02-28

Filing date

1999-08-27

Publication date

2010-12-06

1999-08-27 Application filed by Univ St Louis filed Critical Univ St Louis

1999-08-27 Publication of NO994185D0 publication Critical patent/NO994185D0/no

1999-10-27 Publication of NO994185L publication Critical patent/NO994185L/no

2010-12-06 Publication of NO329693B1 publication Critical patent/NO329693B1/no

Links

241000700605 Viruses Species 0.000 title claims abstract description 117
229960005486 vaccine Drugs 0.000 title claims description 37
150000007523 nucleic acids Chemical class 0.000 title claims description 16
108020004707 nucleic acids Proteins 0.000 title claims description 15
102000039446 nucleic acids Human genes 0.000 title claims description 15
239000000203 mixture Substances 0.000 title claims description 3
108090000623 proteins and genes Proteins 0.000 claims abstract description 102
241000710831 Flavivirus Species 0.000 claims abstract description 99
102000004169 proteins and genes Human genes 0.000 claims abstract description 85
239000002773 nucleotide Substances 0.000 claims abstract description 54
125000003729 nucleotide group Chemical group 0.000 claims abstract description 53
241000710772 Yellow fever virus Species 0.000 claims abstract description 39
229940051021 yellow-fever virus Drugs 0.000 claims abstract description 39
208000015181 infectious disease Diseases 0.000 claims abstract description 26
230000002458 infectious effect Effects 0.000 claims abstract description 19
230000002238 attenuated effect Effects 0.000 claims abstract description 11
241000710842 Japanese encephalitis virus Species 0.000 claims description 106
208000001490 Dengue Diseases 0.000 claims description 24
206010012310 Dengue fever Diseases 0.000 claims description 24
208000025729 dengue disease Diseases 0.000 claims description 24
238000003776 cleavage reaction Methods 0.000 claims description 20
238000010276 construction Methods 0.000 claims description 20
230000007017 scission Effects 0.000 claims description 20
241000711549 Hepacivirus C Species 0.000 claims description 19
208000003152 Yellow Fever Diseases 0.000 claims description 19
108010076504 Protein Sorting Signals Proteins 0.000 claims description 18
208000004006 Tick-borne encephalitis Diseases 0.000 claims description 17
230000015572 biosynthetic process Effects 0.000 claims description 11
241000710886 West Nile virus Species 0.000 claims description 8
230000035772 mutation Effects 0.000 claims description 8
241000725619 Dengue virus Species 0.000 claims description 7
241000710771 Tick-borne encephalitis virus Species 0.000 claims description 7
101710085938 Matrix protein Proteins 0.000 claims description 6
101710127721 Membrane protein Proteins 0.000 claims description 6
208000037404 Central European encephalitis Diseases 0.000 claims description 5
241001466978 Kyasanur forest disease virus Species 0.000 claims description 5
241000725177 Omsk hemorrhagic fever virus Species 0.000 claims description 5
241000710884 Powassan virus Species 0.000 claims description 5
241000907329 Russian Spring-Summer encephalitis virus Species 0.000 claims description 5
241000710888 St. Louis encephalitis virus Species 0.000 claims description 5
206010054261 Flavivirus infection Diseases 0.000 claims description 4
241000710912 Kunjin virus Species 0.000 claims description 4
241000710908 Murray Valley encephalitis virus Species 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
238000011282 treatment Methods 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
206010014596 Encephalitis Japanese B Diseases 0.000 description 88
201000005807 Japanese encephalitis Diseases 0.000 description 88
235000018102 proteins Nutrition 0.000 description 60
210000004027 cell Anatomy 0.000 description 29
238000000034 method Methods 0.000 description 27
239000013612 plasmid Substances 0.000 description 26
239000002299 complementary DNA Substances 0.000 description 25
239000013615 primer Substances 0.000 description 19
238000002474 experimental method Methods 0.000 description 16
239000013598 vector Substances 0.000 description 16
241000699670 Mus sp. Species 0.000 description 15
239000012634 fragment Substances 0.000 description 14
238000000338 in vitro Methods 0.000 description 13
101710204837 Envelope small membrane protein Proteins 0.000 description 11
101710145006 Lysis protein Proteins 0.000 description 11
235000001014 amino acid Nutrition 0.000 description 11
150000001413 amino acids Chemical class 0.000 description 11
108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 9
230000010076 replication Effects 0.000 description 9
201000005805 Murray valley encephalitis Diseases 0.000 description 8
238000012217 deletion Methods 0.000 description 8
230000037430 deletion Effects 0.000 description 8
230000014509 gene expression Effects 0.000 description 8
230000036039 immunity Effects 0.000 description 8
238000001890 transfection Methods 0.000 description 8
108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
206010041896 St. Louis Encephalitis Diseases 0.000 description 7
239000002775 capsule Substances 0.000 description 7
238000010367 cloning Methods 0.000 description 7
230000003472 neutralizing effect Effects 0.000 description 7
210000002845 virion Anatomy 0.000 description 7
108700026244 Open Reading Frames Proteins 0.000 description 6
101710172711 Structural protein Proteins 0.000 description 6
229940124928 YF-Vax Drugs 0.000 description 6
230000008901 benefit Effects 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
238000011081 inoculation Methods 0.000 description 6
239000002671 adjuvant Substances 0.000 description 5
210000000234 capsid Anatomy 0.000 description 5
238000003780 insertion Methods 0.000 description 5
230000037431 insertion Effects 0.000 description 5
238000006386 neutralization reaction Methods 0.000 description 5
238000002255 vaccination Methods 0.000 description 5
238000003556 assay Methods 0.000 description 4
230000007717 exclusion Effects 0.000 description 4
230000028993 immune response Effects 0.000 description 4
230000008520 organization Effects 0.000 description 4
238000012545 processing Methods 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
238000011160 research Methods 0.000 description 4
238000002741 site-directed mutagenesis Methods 0.000 description 4
238000011144 upstream manufacturing Methods 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
241000282412 Homo Species 0.000 description 3
238000012408 PCR amplification Methods 0.000 description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
108020005038 Terminator Codon Proteins 0.000 description 3
108020000999 Viral RNA Proteins 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000008859 change Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
238000010586 diagram Methods 0.000 description 3
238000001114 immunoprecipitation Methods 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
239000002243 precursor Substances 0.000 description 3
238000011084 recovery Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
238000013519 translation Methods 0.000 description 3
108010087967 type I signal peptidase Proteins 0.000 description 3
230000029812 viral genome replication Effects 0.000 description 3
229960001515 yellow fever vaccine Drugs 0.000 description 3
241000710929 Alphavirus Species 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
101710117545 C protein Proteins 0.000 description 2
108090000565 Capsid Proteins Proteins 0.000 description 2
102100023321 Ceruloplasmin Human genes 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
239000003155 DNA primer Substances 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
208000005176 Hepatitis C Diseases 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
101710144111 Non-structural protein 3 Proteins 0.000 description 2
101710144121 Non-structural protein 5 Proteins 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
206010014599 encephalitis Diseases 0.000 description 2
238000001976 enzyme digestion Methods 0.000 description 2
239000000284 extract Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
230000036541 health Effects 0.000 description 2
230000000521 hyperimmunizing effect Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000002427 irreversible effect Effects 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
230000006337 proteolytic cleavage Effects 0.000 description 2
230000005180 public health Effects 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
230000037432 silent mutation Effects 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229940125575 vaccine candidate Drugs 0.000 description 2
210000003501 vero cell Anatomy 0.000 description 2
230000001018 virulence Effects 0.000 description 2
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
208000030090 Acute Disease Diseases 0.000 description 1
208000035145 Arthropod-borne disease Diseases 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
241000711573 Coronaviridae Species 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
241000255925 Diptera Species 0.000 description 1
101150013191 E gene Proteins 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
241000710781 Flaviviridae Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
241000711557 Hepacivirus Species 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
102000003816 Interleukin-13 Human genes 0.000 description 1
108090000176 Interleukin-13 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
102000000743 Interleukin-5 Human genes 0.000 description 1
208000003140 Kyasanur forest disease Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
-1 NS2B Proteins 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
101710152005 Non-structural polyprotein Proteins 0.000 description 1
101800001030 Non-structural protein 2A Proteins 0.000 description 1
101800001020 Non-structural protein 4A Proteins 0.000 description 1
101800001019 Non-structural protein 4B Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
241000710778 Pestivirus Species 0.000 description 1
101710114167 Polyprotein P1234 Proteins 0.000 description 1
101710124590 Polyprotein nsP1234 Proteins 0.000 description 1
241000288906 Primates Species 0.000 description 1
239000004365 Protease Substances 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
208000032108 Russian spring-summer encephalitis Diseases 0.000 description 1
208000009714 Severe Dengue Diseases 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000000240 adjuvant effect Effects 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229940031567 attenuated vaccine Drugs 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
230000000799 fusogenic effect Effects 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
238000012252 genetic analysis Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000003067 hemagglutinative effect Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
229940031551 inactivated vaccine Drugs 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000004726 long-term protective immunity Effects 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
229940035032 monophosphoryl lipid a Drugs 0.000 description 1
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
235000017709 saponins Nutrition 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
210000003956 transport vesicle Anatomy 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000017613 viral reproduction Effects 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Plant Pathology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO19994185A 1997-02-28 1999-08-27 Kimaerisk virus samt anvendelse derav, nukleinsyremolekyl og vaksinesammmensetning. NO329693B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US80744597A	1997-02-28	1997-02-28
US766498A	1998-01-15	1998-01-15
PCT/US1998/003894 WO1998037911A1 (fr)	1997-02-28	1998-03-02	Vaccins chimeres a base de flavivirus

Publications (3)

Publication Number	Publication Date
NO994185D0 NO994185D0 (no)	1999-08-27
NO994185L NO994185L (no)	1999-10-27
NO329693B1 true NO329693B1 (no)	2010-12-06

Family

ID=26677253

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19994185A NO329693B1 (no)	1997-02-28	1999-08-27	Kimaerisk virus samt anvendelse derav, nukleinsyremolekyl og vaksinesammmensetning.

Country Status (20)

Country	Link
EP (3)	EP0977587B1 (fr)
JP (2)	JP4504464B2 (fr)
KR (1)	KR100517323B1 (fr)
CN (1)	CN1187088C (fr)
AT (2)	ATE297757T1 (fr)
AU (1)	AU740961B2 (fr)
BR (1)	BR9807873A (fr)
CA (1)	CA2282790C (fr)
CZ (1)	CZ300172B6 (fr)
DE (2)	DE69841690D1 (fr)
DK (2)	DK1625852T3 (fr)
ES (2)	ES2345614T3 (fr)
HU (1)	HU228705B1 (fr)
IL (4)	IL131600A0 (fr)
NO (1)	NO329693B1 (fr)
NZ (1)	NZ337522A (fr)
PL (1)	PL192957B1 (fr)
PT (2)	PT1625852E (fr)
RU (1)	RU2209082C2 (fr)
WO (1)	WO1998037911A1 (fr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6962708B1 (en)	1997-02-28	2005-11-08	Acambis, Inc.	Chimeric flavivirus vaccines
US7227011B2 (en) *	1998-06-04	2007-06-05	United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention	Nucleic acid vaccines for prevention of flavivirus infection
US7417136B1 (en)	1998-06-04	2008-08-26	The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention	Nucleic acid vaccines for prevention of flavivirus infection
US7009044B1 (en) *	1999-06-04	2006-03-07	The United States Of America As Represented By The Department Of Health And Human Services	HCV/BVDV chimeric genomes and uses thereof
US7425437B2 (en)	1999-11-26	2008-09-16	Crucell Holland B.V.	Vaccines against West Nile Virus
AU1813901A (en) *	1999-12-01	2001-06-12	Oravax, Inc	Chimeric flavivirus vaccines
US6589531B1 (en) *	2000-01-21	2003-07-08	The Regents Of The University Of California	Recombinant yellow fever virus and method of use thereof
WO2001059093A2 (fr) *	2000-02-10	2001-08-16	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	CLONES D'ADNc INFECTIEUX DE PLEINE LONGUEUR DE FLAVIVIRUS A TIQUES
CA2941182A1 (fr) *	2000-02-16	2001-08-23	The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Flavivirus chimeriques avirulents et immunogenes
RS20100015A (sr) *	2001-01-26	2010-12-31	Schering Corporation	Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
AU2007202304B2 (en) *	2001-04-04	2010-03-18	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION	Nucleic acid vaccines for prevention of flavivirus infection
FR2823222B1 (fr) *	2001-04-06	2004-02-06	Merial Sas	Vaccin contre le virus de la fievre du nil
US7740863B2 (en)	2001-04-06	2010-06-22	Merial	Recombinant vaccine against West Nile Virus
US20030232324A1 (en)	2001-05-31	2003-12-18	Chiron Corporation	Chimeric alphavirus replicon particles
AU2002303330B2 (en) *	2001-05-31	2008-07-24	Novartis Vaccines And Diagnostics, Inc.	Chimeric alphavirus replicon particles
PL371187A1 (en)	2001-06-01	2005-06-13	Acambis, Inc.	Chimeric flavivirus vectors
US6682883B1 (en) *	2001-07-19	2004-01-27	Acambis, Inc.	Diagnosis of flavivirus infection
DK1441761T3 (da) *	2001-10-19	2007-08-27	Acambis Inc	Fremgangsmåder til forebyggelse og behandling af flavivirus-infektion hos dyr
CA2467397A1 (fr) *	2001-11-26	2003-06-05	Replikun Biotech Pty Ltd	Systeme d'administration d'un vaccin a base de flavivirus
JP2005519639A (ja)	2002-01-15	2005-07-07	アカンビスインコーポレーティッド	フラビウイルスワクチン
DK1375670T3 (da) *	2002-06-20	2013-09-23	Pasteur Institut	Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger
EP2110382A1 (fr)	2002-06-20	2009-10-21	Institut Pasteur	ADNc infectieux pour une souche de vaccin améliorée du virus de la rougeole Utilisation pour compositions immunogènes
AU2003256532A1 (en) *	2002-07-19	2004-02-09	Board Of Regents, The University Of Texas System	Methods and compositions concerning altered yellow fever virus strains
AU2003290985B2 (en)	2002-11-15	2010-04-01	Acambis Inc.	West nile virus vaccine
CA2432738A1 (fr)	2003-02-26	2004-08-26	Philippe Despres	Nouvelles proteines des virus de la dengue et du nil et genes codant pour ces proteines, et leurs utilisations dans des vaccins et dans des applications therapeutiques et diagnostiques
CN1304579C (zh) *	2003-07-21	2007-03-14	上海天甲生物医药有限公司	重组的以黄热病病毒为载体的疫苗
WO2005040390A1 (fr) *	2003-07-21	2005-05-06	Shanghai Tengen Biomedical Co., Ltd.	Vaccin recombine utilisant le virus de la fievre jaune comme vecteur
CN103088038B (zh) *	2004-07-12	2015-06-24	美国天甲生物医药有限公司	黄病毒疫苗
WO2006044857A2 (fr) *	2004-10-20	2006-04-27	Acambis Inc.	Vaccins contre le virus de l'encephalite japonaise et le virus du nil occidental
CA2591665C (fr)	2004-12-20	2015-05-05	Crucell Holland B.V.	Molecules de liaison capables de neutraliser le virus du nil occidental et utilisations correspondantes
AU2005320001B2 (en)	2004-12-24	2011-05-19	The Research Foundation For Microbial Diseases Of Osaka University	Attenuated chimeric flavivirus bearing attenuated Japanese encephalitis virus gene as backbone
CN103031279B (zh)	2005-04-24	2015-11-18	赛诺菲巴斯德生物制药有限责任公司	重组黄病毒疫苗
WO2006120230A2 (fr)	2005-05-12	2006-11-16	Crucell Holland B.V.	Molecules de liaison specifiques de cellule hote capables de neutraliser des virus et leurs utilisations
BRPI0504945B8 (pt)	2005-10-31	2022-08-02	Fundacao Oswaldo Cruz	Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.
CU23586A1 (es)	2005-11-22	2010-10-30	Ct Ingenieria Genetica Biotech	Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CN103351435B (zh)	2006-06-06	2015-08-19	克鲁塞尔荷兰公司	具有杀灭葡萄球菌活性的人结合分子及其应用
RU2009105099A (ru)	2006-07-14	2010-08-27	Санофи Пастер Байолоджикс Ко. (Us)	Конструирование рекомбинантных вирусных вакцин путем прямой транспозон-опосредованной инсерции чужеродных иммунологических детерминант в белки векторного вируса
FR2906724B1 (fr)	2006-10-04	2009-03-20	Sanofi Pasteur Sa	Methode d'immunisation contre les 4 serotypes de la dengue.
CA2668834C (fr)	2006-11-07	2016-10-11	Sanofi Pasteur Biologics Co.	Stabilisation de vaccins par lyophilisation
US8486417B2 (en)	2007-01-31	2013-07-16	Sanofi Pasteur Biologics, Llc	Recombinant bicistronic Flavivirus vectors
EP2117588A4 (fr) *	2007-02-09	2011-05-04	Sanofi Pasteur Biologics Co	Vecteurs viraux et procedes d'utilisation
ES2615390T3 (es)	2008-03-05	2017-06-06	Sanofi Pasteur	Proceso para estabilizar una composición de vacuna que contiene adyuvante
JP5779352B2 (ja)	2008-03-14	2015-09-16	サノフィパスツールバイオロジクスリミテッドライアビリティカンパニー	複製欠損フラビウイルスワクチンおよびワクチンベクター
EP2143440A1 (fr)	2008-07-09	2010-01-13	Sanofi Pasteur	Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
EP2353609A1 (fr)	2010-02-04	2011-08-10	Sanofi Pasteur	Compositions et procédés d'immunisation
MY168959A (en)	2012-07-24	2019-01-28	Sanofi Pasteur	Vaccine compositions for the prevention of dengue virus infection
CA2878599A1 (fr)	2012-07-24	2014-01-30	Jiansheng Yao	Compositions de vaccin pour prevenir une infection provoquee par le virus de la dengue
WO2014053246A1 (fr)	2012-10-03	2014-04-10	Sanofi Pasteur	Vaccination contre l'encéphalite japonaise, la rougeole, les oreillons et la rubéole
BR112015012515B1 (pt)	2012-11-30	2023-04-11	Sanofi Pasteur	Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
CA3177572C (fr)	2013-03-15	2026-02-03	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Compositions et procedes pour constructions chimeriques du virus de la dengue dans des vaccins
MX366154B (es)	2013-06-21	2019-06-28	Merck Sharp & Dohme	Composiciones de vacuna del virus del dengue y metodos de uso de las mismas.
CN103352029A (zh) *	2013-07-29	2013-10-16	中国人民解放军军事医学科学院微生物流行病研究所	一种乙脑/森林脑炎嵌合病毒及其应用
TWI852899B (zh)	2014-09-02	2024-08-21	法商賽諾菲巴斯德公司	疫苗組合物
EP3031923A1 (fr) *	2014-12-11	2016-06-15	Institut Pasteur	Composition immunogène contre l'encéphalite japonaise à base de vecteurs lentiviraux
MY192543A (en)	2014-12-22	2022-08-26	Merck Sharp & Dohme	Dengue virus vaccine compositions and methods of use thereof
US10857222B2 (en)	2015-07-03	2020-12-08	Sanofi Pasteur	Concomitant dengue and yellow fever vaccination
WO2017109698A1 (fr)	2015-12-22	2017-06-29	Glaxosmithkline Biologicals Sa	Formulation immunogène
CN105400799B (zh) *	2015-12-22	2018-12-28	成都生物制品研究所有限责任公司	一种乙脑/黄热嵌合病毒及其制备方法和应用
GB201716307D0 (en) *	2017-10-05	2017-11-22	Univ Leuven Kath	Chimeric yellow fever zika virus strain
AU2018346724B2 (en)	2017-10-05	2025-01-09	Sanofi Pasteur	Compositions for booster vaccination against dengue
WO2019212312A1 (fr) *	2018-05-04	2019-11-07	에스케이바이오사이언스 주식회사	Vaccin chimère contre le virus zika
US11464815B2 (en)	2018-09-05	2022-10-11	Takeda Vaccines, Inc.	Dengue vaccine unit dose and administration thereof
US11426461B2 (en)	2018-09-05	2022-08-30	Takeda Vaccines, Inc.	Methods for preventing dengue and hepatitis A
CN112912106A (zh)	2018-09-05	2021-06-04	武田疫苗股份有限公司	登革热疫苗单位剂量及其施用
WO2020051328A1 (fr)	2018-09-05	2020-03-12	Takeda Vaccines, Inc.	Dosage permettant de déterminer la réponse d'un anticorps au virus de la dengue
GB201814563D0 (en) *	2018-09-07	2018-10-24	Univ Leuven Kath	Chimeric flavivirus lyssavirus vaccines
MX2022001742A (es)	2019-08-16	2022-04-07	Takeda Vaccines Inc	Metodos para prevenir el dengue y la hepatitis a.
EP4110381A1 (fr)	2020-02-27	2023-01-04	Takeda Vaccines, Inc.	Procédé d'élimination d'adn de cellule hôte à partir d'une préparation virale
CN113215116B (zh) *	2021-05-11	2022-07-19	中国科学院动物研究所	基于朝阳病毒载体的嵌合病毒、疫苗及其应用
CN117751183A (zh) *	2021-05-27	2024-03-22	迈凯恩技术有限公司	使用假病毒的抗体依赖性感染增强反应的评价方法
WO2023147342A2 (fr)	2022-01-25	2023-08-03	Takeda Vaccines, Inc.	Production et fabrication de vaccin flaviviral à grande échelle
WO2023158989A1 (fr)	2022-02-15	2023-08-24	Takeda Vaccines, Inc.	Processus d'agitation par lots de vaccin contre la dengue
EP4519847A1 (fr)	2022-05-04	2025-03-12	Takeda Vaccines, Inc.	Détermination par ordinateur d'une infectivité de flavivirus
US20260078403A1 (en) *	2022-11-07	2026-03-19	The Regents Of The University Of California	Zikv-based gene delivery system
CN120225693A (zh)	2022-11-18	2025-06-27	武田疫苗股份有限公司	测定制剂中具有包含至少一个减毒基因座的核苷酸序列的活减毒黄病毒的比例的方法
CN120529951A (zh)	2022-11-29	2025-08-22	武田疫苗股份有限公司	大规模黄病毒疫苗生产和制造
WO2025072259A1 (fr)	2023-09-25	2025-04-03	Takeda Vaccines, Inc.	Coadministration d'un vaccin tétravalent contre la dengue avec un vaccin contre le vph
WO2025122855A1 (fr)	2023-12-08	2025-06-12	Takeda Vaccines, Inc.	Procédé pour déterminer la concentration de l'adn génomique résiduel des cellules vero dans un échantillon contenant un virus obtenu après production dans des cellules vero
WO2026077983A1 (fr)	2024-10-08	2026-04-16	Sanofi R&D Vaccins	Compositions et procédés de stabilisation de flavivirus vivants atténués

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL91304A0 (en) *	1988-08-20	1990-03-19	Us Health	Recombinant vaccinia virus for prevention of disease caused by flavivirus
US5494671A (en) *	1990-08-27	1996-02-27	The United States Of America As Represented By The Department Of Health And Human Services	C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
DE69230316T2 (de) *	1991-09-19	2000-07-13	Us Health	Chimäre und/oder wachstumsgehemmte flaviviren

1998
- 1998-03-02 CA CA2282790A patent/CA2282790C/fr not_active Expired - Lifetime
- 1998-03-02 DK DK05012770.3T patent/DK1625852T3/da active
- 1998-03-02 AT AT98910103T patent/ATE297757T1/de active
- 1998-03-02 PT PT05012770T patent/PT1625852E/pt unknown
- 1998-03-02 BR BR9807873A patent/BR9807873A/pt not_active Application Discontinuation
- 1998-03-02 PL PL335481A patent/PL192957B1/pl unknown
- 1998-03-02 RU RU99120696/14A patent/RU2209082C2/ru active
- 1998-03-02 KR KR10-1999-7007904A patent/KR100517323B1/ko not_active Expired - Lifetime
- 1998-03-02 ES ES05012770T patent/ES2345614T3/es not_active Expired - Lifetime
- 1998-03-02 PT PT98910103T patent/PT977587E/pt unknown
- 1998-03-02 HU HU0002139A patent/HU228705B1/hu unknown
- 1998-03-02 CN CNB988045567A patent/CN1187088C/zh not_active Expired - Lifetime
- 1998-03-02 IL IL13160098A patent/IL131600A0/xx not_active IP Right Cessation
- 1998-03-02 DE DE69841690T patent/DE69841690D1/de not_active Expired - Lifetime
- 1998-03-02 EP EP98910103A patent/EP0977587B1/fr not_active Expired - Lifetime
- 1998-03-02 AT AT05012770T patent/ATE468858T1/de active
- 1998-03-02 ES ES98910103T patent/ES2244050T3/es not_active Expired - Lifetime
- 1998-03-02 EP EP05012770A patent/EP1625852B1/fr not_active Expired - Lifetime
- 1998-03-02 JP JP53790798A patent/JP4504464B2/ja not_active Expired - Lifetime
- 1998-03-02 EP EP10005372A patent/EP2251036A1/fr not_active Withdrawn
- 1998-03-02 DK DK98910103T patent/DK0977587T3/da active
- 1998-03-02 NZ NZ337522A patent/NZ337522A/en not_active IP Right Cessation
- 1998-03-02 DE DE69830579T patent/DE69830579T2/de not_active Expired - Lifetime
- 1998-03-02 WO PCT/US1998/003894 patent/WO1998037911A1/fr not_active Ceased
- 1998-03-02 AU AU64431/98A patent/AU740961B2/en not_active Expired
- 1998-03-02 CZ CZ0306499A patent/CZ300172B6/cs not_active IP Right Cessation
1999
- 1999-08-27 NO NO19994185A patent/NO329693B1/no not_active IP Right Cessation
2008
- 2008-07-31 IL IL193170A patent/IL193170A/en not_active IP Right Cessation
2009
- 2009-10-28 JP JP2009247641A patent/JP2010057496A/ja active Pending
2010
- 2010-08-10 IL IL207517A patent/IL207517A0/en unknown
- 2010-08-10 IL IL207516A patent/IL207516A0/en unknown

Also Published As

Publication number	Publication date
IL193170A (en)	2015-08-31
DK1625852T3 (da)	2010-09-20
HUP0002139A3 (en)	2001-10-29
EP2251036A1 (fr)	2010-11-17
RU2209082C2 (ru)	2003-07-27
CZ300172B6 (cs)	2009-03-04
ES2244050T3 (es)	2005-12-01
AU6443198A (en)	1998-09-18
EP1625852B1 (fr)	2010-05-26
CA2282790C (fr)	2011-04-19
EP0977587B1 (fr)	2005-06-15
JP4504464B2 (ja)	2010-07-14
JP2010057496A (ja)	2010-03-18
JP2001514622A (ja)	2001-09-11
PL192957B1 (pl)	2006-12-29
KR20000075830A (ko)	2000-12-26
PT1625852E (pt)	2010-08-27
CA2282790A1 (fr)	1998-09-03
EP1625852A1 (fr)	2006-02-15
WO1998037911A1 (fr)	1998-09-03
EP0977587A1 (fr)	2000-02-09
DE69830579D1 (de)	2005-07-21
ATE468858T1 (de)	2010-06-15
NZ337522A (en)	2001-02-23
NO994185D0 (no)	1999-08-27
DE69841690D1 (de)	2010-07-08
AU740961B2 (en)	2001-11-15
IL207516A0 (en)	2010-12-30
IL193170A0 (en)	2009-02-11
IL131600A0 (en)	2001-01-28
PT977587E (pt)	2005-10-31
KR100517323B1 (ko)	2005-09-27
PL335481A1 (en)	2000-04-25
HU228705B1 (en)	2013-05-28
DE69830579T2 (de)	2006-05-04
CN1253506A (zh)	2000-05-17
CZ306499A3 (cs)	2000-01-12
DK0977587T3 (da)	2005-10-17
NO994185L (no)	1999-10-27
IL207517A0 (en)	2010-12-30
BR9807873A (pt)	2000-03-21
ATE297757T1 (de)	2005-07-15
HK1025743A1 (en)	2000-11-24
HUP0002139A2 (hu)	2000-10-28
EP0977587A4 (fr)	2000-08-02
ES2345614T3 (es)	2010-09-28
CN1187088C (zh)	2005-02-02

Legal Events

Date	Code	Title	Description
2018-03-12	MK1K	Patent expired

Publication	Publication Date	Title
AU740961B2 (en)	2001-11-15	Chimeric flavivirus vaccines
US6962708B1 (en)	2005-11-08	Chimeric flavivirus vaccines
WO1998037911A9 (fr)	1999-02-11	Vaccins chimeres a base de flavivirus
US8029802B2 (en)	2011-10-04	Vaccines against Japanese encephalitis virus and West Nile virus
WO2001039802A9 (fr)	2002-05-16	Vaccins de flavivirus chimere
EP1366170A1 (fr)	2003-12-03	Utilisation de flavivirus pour exprimer des epitopes proteiques et developpement de nouveaux virus vivants attenues utilises comme vaccin pour immuniser contre flavivirus et d'autres agents infectieux
CN103031279B (zh)	2015-11-18	重组黄病毒疫苗
Galler et al.	1997	The yellow fever 17D vaccine virus: molecular basis of viral attenuation and its use as an expression vector
CN101084010B (zh)	2015-05-06	抗日本脑炎病毒及西尼罗病毒的疫苗
CA2400182C (fr)	2011-06-28	Clones d'adnc infectieux de pleine longueur de flavivirus a tiques
MXPA99007949A (es)	2000-08-01	Vacunas de flavivirus quimerico
HK1149708A (en)	2011-10-14	Chimeric flavivirus vaccines
HK1092049A (en)	2007-02-02	Chimeric flavivirus vaccines
HK1025743B (en)	2005-10-21	Chimeric flavivirus vaccines
HK1120431A (en)	2009-04-03	Recombinant flavivirus vaccines
HK1106723B (en)	2015-10-30	Vaccines against japanese encephalitis virus and west nile virus